Teva, Amgen resolve generic Sensipar dispute
Teva is putting its generic Sensipar on hold for a few years.
The company recently settled an ongoing dispute with Sensipar maker Amgen, agreeing to stop selling the generic version until its license date in mid-2021, or earlier under certain circumstances.
The settlement puts to bed an ongoing patent infringement suit that followed Teva launching its generic Senspiar after getting it approved by the Food and Drug Administration. Teva will pay Amgen an undisclosed amount as part of the settlement. That amount, as well as other terms, remains confidential.
Sensipar (cinacalcet HCl) is a calcium-sensing receptor agonist indicated for secondary hyperparathyroidism, or HPT, in adult patients with chronic kidney disease on dialysis. It also is used for the treatment of hypercalcemia in adult patients with parathyroid carcinoma and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.
The company recently settled an ongoing dispute with Sensipar maker Amgen, agreeing to stop selling the generic version until its license date in mid-2021, or earlier under certain circumstances.
The settlement puts to bed an ongoing patent infringement suit that followed Teva launching its generic Senspiar after getting it approved by the Food and Drug Administration. Teva will pay Amgen an undisclosed amount as part of the settlement. That amount, as well as other terms, remains confidential.
Sensipar (cinacalcet HCl) is a calcium-sensing receptor agonist indicated for secondary hyperparathyroidism, or HPT, in adult patients with chronic kidney disease on dialysis. It also is used for the treatment of hypercalcemia in adult patients with parathyroid carcinoma and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.